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Cigarette smoking and cerebral 
microvasculature in patients  
with type 1 diabetes: a pilot study
ABSTRACT
Introduction. A decrease in vasomotor reactivity reserve (VMRr) or an increase in pulsatility index (PI) 
are the early signs of cerebral microangiopathy in type 1 diabetes. Cigarette smoking is a risk factor for 
microvascular complications of type 1 diabetes, but cigarette smokers are routinely excluded from studies 
on VMRr or PI in type 1 diabetes (T1DM) and there is no evidence of any significant impact of smoking 
on these variables in T1DM. Therefore, we aimed to assess the impact of cigarette smoking on VMRr 
and PI in these patients.
Methods. VMRr and PI of the middle cerebral artery were measured with Transcranial Doppler in 79 patients 
with T1DM (median age 33.0 years, range 20–51, 44% males) without a history of cerebrovascular events, 
coronary heart disease or carotid stenosis. The relationship between cigarette smoking (n = 20, mean 
pack-years 9.4 ± 6.1) and VMRr, PI, concomitant risk factors, medications and the presence of systemic 
microvascular complications were analysed.
Results. Smokers and non-smokers did not differ in terms of their clinical characteristics, with an exception 
of higher circadian insulin demand in smokers (60 ± 12.9 v. 49.2 ± 14.2 units; p = 0.004). A correlation 
between pack-years and PI (r = 0.6, p = 0.004), but not with VMRr, was found in smokers. However, no 
significant differences between smokers and non-smokers were found regarding either VMRr (mean 85.9 
±  20% v. 84.1 ± 20.1%; p = 0.74) or PI (median 0.85, range 0.61–1.09 v. 0.88, range 0.48–1.52; p = 0.2).
Conclusions. We did not prove any significant impact of smoking on VMRr in T1DM patients, but the 
association between pack-years and PI may indicate the negative impact of intensive cigarette smoking 
on the cerebral microvasculature in type 1 diabetes. 
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Introduction
Cigarette smoking is considered a risk factor for 
the development of microvascular complications of 
type 1 diabetes mellitus, both diabetic nephro- and ret-
inopathy [1–4]. It has also been reported that cigarette 
smoking increases the risk of diabetic neuropathy in 
patients with type 1 diabetes [5]. 
Cerebral microangiopathy can be reflected by a de-
crease in vasomotor reactivity reserve (VMRr) or an in-
crease in pulsatility index (PI) [6–10]. However, smokers 
have not been included in the previous studies that showed 
VMR impairment in patients with type 1 diabetes [6–9]. 
The rationale for excluding smokers from the studies on 
VMRr in patients with type 1 diabetes is probably based 
on the short-term effect of cigarette smoking on CO2-in-
duced vasomotor reactivity in healthy subjects [11–12]. 
However, it remains unclear whether long-time effects of 
smoking on VMRr exist in humans who are independent 
of the presence of vascular risk factors.
Thus, in the present study, we aimed to assess the 
long-time effect of cigarette smoking on cerebral vessel 
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reactivity or pulsatility in patients with type 1 diabetes 
without advanced diabetic complications or prior cere-
brovascular events.
Methods
The study was performed as a continuation of 
a previously published one and was based on a similar 
research protocol and methods [9].
Patients and controls
The study population consisted of 79 patients with 
type 1 diabetes (44 women and 35 men, median age 
33.0 years, range limits 20–51 years). Study group com-
bined a sample of 59 non-smokers who have already 
been reported for the presence of VMRr impairment 
and a new sample of 20 smokers recruited from the 
Regional Diabetological Centre of Medical University of 
Gdańsk [9]. We included patients with minimal diabetes 
duration of two years, free of focal neurological deficits, 
respiratory tract disease (at present and in the history) 
and renal insufficiency. We excluded patients with past 
cerebrovascular events or head trauma, pregnant wom-
en, heavy drinkers, subjects with incidents of severe 
hypoglycaemia within 30 days prior to the initiation of 
the study and users of any hormonal therapy within 
30 days prior to the initiation of the study. 
All examinations were performed under stan-
dardised conditions at the same time of the day (be-
tween 10:00 a.m. and 2:00 p.m.). All participants were 
asked not to drink coffee for 12 h before the examina-
tion, to avoid sleep deprivation, and to eat normal meals 
the day before the examination. Smokers were asked 
not to smoke for 2 h before the examination.
The study protocol included history taking, neu-
rological examination, extracranial and transcranial 
ultrasound, fundoscopy and laboratory testing. The 
study protocol was approved by the Medical Eth-
ics Committee of the Medical University of Gdańsk 
(NKEBN/3/2005 and NKEBN/335/2008). Upon entry, 
each participant gave her/his informed consent.
Subject characteristics
Patient history was obtained including information 
on past and current disorders, cigarette smoking hab-
its (active or past, number of pack-years) as well as 
co-morbid conditions and treatment. Weight and height 
were recorded and expressed as the body mass index 
(BMI). Focal neurological deficits were excluded by 
neurological examination performed by a neurologists 
certified by the Polish Neurological Society. Diabetic 
neuropathy was diagnosed using the criteria of the 
Neurological Symptom Score (NSS) based on patient’s 
complaints and neuropathic deficits found upon neuro-
logical examination [13]. Hypertension was diagnosed 
if two consecutive measurements of systolic or diastolic 
blood pressure exceeded 140 mm Hg and 90 mm Hg, 
respectively, or if anti-hypertensive medication was 
used [14].
Laboratory examinations in patients with type 1 di-
abetes included measurements of 24 h urinary protein 
or microalbuminuria, total serum cholesterol and 
glycated haemoglobin (HbA1c). The biochemical ex-
aminations were performed at least 1 month (±7 days) 
prior to Transcranial Doppler (TCD). Hyperlipidaemia 
was diagnosed if total cholesterol and/or triglycerides 
exceeded 175 mg/dL and 150 mg/dL, respectively, 
or if cholesterol/triglyceride-lowering medications 
were used [15]. Nephropathy was diagnosed if the 
excretion of albumin in 24 h exceeded 30 mg in two 
of three urine collections repeated at intervals of up to 
6 months, with both readings in the presence of micro-
albuminuria and overt nephropathy [16]. Quantitative 
measurements of urine protein excretion in a sample 
obtained from 24 h urine collection were used to 
assess the severity of proteinuria. The albumin and 
protein concentrations in urine were measured by the 
turbidimetric method.
Fundoscopy
Retinopathy was recognised on fundoscopy per-
formed by an ophthalmologist certified by the Polish 
Ophthalmological Society. Grading was assessed 
through the use of the Stages of Diabetic Retinopathy 
scale of the American Academy of Ophthalmology 
(AAO). Previous therapy with photocoagulation was 
also recognised as a marker of diabetic retinopathy [17].
Carotid Doppler examination 
Standard examinations of both carotid arteries 
were performed by well-trained investigators (KBK 
with 12 years of experience and GK with 11 years of 
experience) using Aloka 5000 ultrasound device (Alo-
ka Co., Ltd, Japan) equipped with a linear probe with 
a central working frequency of 7.5 MHz and range limits 
of 5–10 MHz or Vivid I device (GE Healthcare, USA) 
equipped with a linear probe with a central working 
frequency of 6.3 MHz and range limits of 3.96–8.4 MHz.
Transcranial Doppler examination 
Middle cerebral artery (MCA) flow parameters were 
measured by TCD through the temporal bone window 
using MultiDop T2 DWL device (DWL Elektronische Sys-
teme, Singen, Germany) equipped with a 2 MHz pulse 
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wave probe. Velocity measurements were performed 
simultaneously in both MCA by one well-trained ultraso-
nographer (GK) using a two-channel monitoring kit: two 
probes at 2 MHz PW, a fixation band and a monitoring 
programme (MF version 8.27 L, DWL). The physiolog-
ical technique of provoking cerebrovascular reactivity 
by changes in pCO2 was applied according to the 
published standards [18–19]. During the CO2 reactivity 
test, the CO2 content in expired air (end-tidal CO2 con-
centration) was monitored continuously (capnograph 
Datex Normocap, Helsinki, Finland). Before and after 
the tests, the systemic blood pressure was measured. 
The vasomotor reactivity reserve expressed as a per-
cent change from baseline was calculated according 
to a standard protocol published previously [18–19]. 
The median values of the arithmetic means of the ve-
locity measurements at rest (rest Vmean), VMRr and 
the Pulsatility Index (PI) of both MCAs were used for 
further analyses.
Statistics
All the statistical analyses were performed with 
STATISTICA, version 9.1 (StatSoft Inc, Tulsa, OK). 
Shapiro-Wilk tests were performed to analyse the dis-
tribution of continuous variables. Differences between 
groups were analysed with Student’s t-test in the case 
of normally distributed variables (circadian insulin de-
mand, VMRr) or with the Mann-Whitney U test in the 
case of non-normally distributed variables (age, type 
1 diabetes duration, BMI, diastolic and systolic blood 
pressure, rest Vmean, PI, end tidal CO2 concentration). 
The Chi-square test was used to compare the proportion 
of females to males, the prevalence of systemic micro-
vascular complications and concomitant risk factors in 
groups. Correlation was assessed by the Spearman’s 
rank correlation test. The level of p < 0.05 was regarded 
as statistically significant.
Results
Twenty patients (25.3%) reported active smoking 
(range from 0.75 to 18 pack-years, mean 9.28 ± 6.08). 
There were no past smokers in the study group consid-
ering both, period of 5 years prior to the study as well 
as the entire previous history.
Based on medical history, physical examination, bio-
chemical analysis, carotid and transcranial ultrasound, 
none of the study subjects had an established diagnosis 
of coronary heart disease, diabetic foot, orthostatic 
hypotension, chronic renal insufficiency or significant 
stenosis (> 50%) of the extra- and intracranial arteries. In 
spite of the higher mean circadian insulin demand in 
smoking than in non-smoking patients (60 ± 12.9 v. 
49.2 ± 14.2 units; p = 0.004), both groups did not 
differ in terms of age, gender, diabetes duration, BMI, 
systolic and diastolic blood pressure or prevalence of 
systemic microvascular complications and co-morbid-
ities (Tab. 1).
We found a significant correlation between PI and 
pack-years in the subgroup of smoking patients with 
type 1 diabetes (r = 0.61, p = 0.004) (Fig. 1). No sig-
nificant correlation between VMRr and pack-years was 
observed (r = 0.18, p = 0.42). We found no significant 
differences between smoking and non-smoking patients 
regarding mean VMRr (85.9 ± 20 v. 84.1 ± 20.1%; 
p = 0.74) or median PI (0.85, range 0.61–1.09 v. 0.88, 
range 0.48–1.52; p = 0.2). No differences between the 
groups existed regarding MCA mean flow velocities at 
rest, or in the median end-tidal CO2 concentrations after 
hyperventilation or after breath-holding (Tab.1).
Discussion
This pilot study indicates that long-term effects of 
cigarette smoking do not influence cerebral vasomotor 
reactivity in patients with type 1 diabetes. Nevertheless, 
our study reveals a correlation between pack-years and 
PI, which may indicate the negative influence of inten-
sive cigarette smoking on the cerebral microvasculature 
in type 1 diabetes. 
To the best of our knowledge, no published data 
exist on the correlation between smoking and VMRr in 
patients with type 1 diabetes. To date, only the short-
term negative effects of smoking on VMRr have been 
reported in groups of healthy subjects [11–12]. Thus, 
we cannot contrast our results with the findings of oth-
er authors due to the lack of similar reports. Similarly, 
reports on PI in diabetes are sparse, and no correlation 
between cerebral pulsatility and smoking load has yet 
been shown [20]. Therefore, regardless of the nega-
tive results, we believe that our findings broaden the 
knowledge about the risk factors for the development 
of cerebral microangiopathy in diabetes.
Our findings are in line with some reports that show no 
contribution of smoking to the development of diabetic 
nephropathy and retinopathy in type 1 diabetes [21, 22]. 
Similarly, we have not found any significant differences 
between the subgroups of smoking and non-smoking 
patients regarding the prevalence of nephropathy and 
retinopathy. The only difference between the studied 
groups was a higher circadian insulin demand in smok-
ing patients. This is in agreement with a previous report 
which investigated increased insulin requirements in 
smokers with type 1 diabetes [23].
However, despite the lack of an association between 
smoking and VMRr, we cannot deny a negative impact 
of smoking on the cerebral microvasculature in type 1 
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Age (years) 32 (21–51) 35.5 (20–49) 0.08
F:M ratio 34:25 10:10 0.55; c2 0.35 
BMI [kg/m2] 24.1 (20.1–31.6) 25.5 (20.8–33.5) 0.18
Systolic blood pressure [mm Hg] 122 (98–145) 124 (98–175) 0.68
Diastolic blood pressure [mm Hg] 80 (45–98) 80 (49–95) 0.11
Hyperlipidaemia (%) 67.8 70.0 0.85; c2 = 0.03
Arterial Hypertension (%) 15.0 20.3 0.84; c2 = 0.04
Neuropathy (%) 25.4 20,0 0.85; c2 = 0.03
Retinopathy(%) 42.4 50.0 0.55; c2 = 0.35
Nephropathy(%) 15.2 15.0 0.11; c2 = 0.73
Type 1 diabetes duration (years) 15.0 (3–33) 14.0 (5–35) 0.70
HbA1C (%) 7.8 (5.9–12.0) 7.9 (6.4–11.9) 0.65
Daily insulin demand [U] 49.2 ± 14.2 60.0 ± 13.0 <0.01
ACEI or ARB treatment (%) 16.9 10.0 0.70; c2 = 0.15
Statin treatment (%) 10.2 15.0 0.86; c2 = 0.03
Rest Vmean [cm/s] 60.2 (35.8–106.5) 62.9 (32.1–110.0) 0.43
Pulsatility index 0.88 (0.48–1.52) 0.85 (0.61–1.09) 0.20
VMRr (%) 84.1 ± 20.1 85.9 ± 20.0 0.74
Delta etCO2 HV(%) 1.7 (1.0–2.5) 1.8 (1.1–2.5) 0.31
Delta etCO2 BH(%) 1.1 (0.5–2.0) 1.2 (0.7–1.7) 0.26
F:M ratio — female to male ratio; BMI — body mass index; HbA1c — glycated haemoglobin; ACEI — angiotensin–converting enzyme inhibitor; 
ABR — angiotensin receptor blocker, Rest Vmean — mean flow velocity measured at rest; VMRr — vasomotor reactivity reserve; Delta etCO2HV — 
delta end–tidal CO2 during hyperventilation; Delta etCO2 BH — delta end–tidal CO2 during breath holding
Figure 1. Correlation between PI and pack-years in a subgroup of smoking patients with type 1 diabetes
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diabetes. The correlation between cerebral pulsatility 
and smoking load indicates an association between the 
intensive tobacco use and the development of cerebral 
microangiopathy in type 1 diabetes. We also believe 
that our data indicate a different impact of smoking on 
systemic and cerebral microcirculatory dysfunction. Thus 
we find the rationale for further studies on VMRr in larger, 
population-based cohorts of patients with type 1 diabetes.
Conclusions
The intensive tobacco use may play a role in the 
development of cerebral microangiopathy in type 1 di-
abetes, which is reflected by the increase of cerebral 
pulsatility measured with transcranial Doppler.
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